All In Biotech

Drug Trial Radar · NCT00822393

Clinical Phase III Trial Treosulfan-based Conditioning Versus Reduced-intensity Conditioning (RIC)

Clinical Phase III Trial to Compare Treosulfan-based Conditioning Therapy With Busulfan-based Reduced-intensity Conditioning (RIC) Prior to Allogeneic Haematopoietic Stem Cell Transplantation in Patients With AML or MDS Considered Ineligible to Standard Conditioning Regimens

Last checked: Nov 20, 2026Latest source record: Jul 30, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 570 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

570

Actual

Start

Nov 24, 2008

Primary completion

Jan 25, 2018

Study completion Jan 25, 2018

Sponsor

Lead sponsor
medac GmbHIndustry
Sponsor type
Industry
First posted
Jan 14, 2009

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This randomized allogeneic transplantation protocol compares i.v. Treosulfan-based conditioning therapy with reduced intensity i.v. Busulfan-based conditioning in adult AML and MDS patients at increased risk for standard conditioning therapies. The protocol is based on results of previous phase I/II trials evaluating Treosulfan/Fludarabine conditioning prior to allogeneic haematopoietic stem cell transplantation. The reference arm (reduced intensity i.v. Busulfan/Fludarabine) is considered to be accepted medical practice for the study patient population.

Conditions

  • Acute Myeloid Leukemia
  • Myelodysplastic Syndrome

Interventions

  • BusulfanDrug

    4 x 0.8 mg/kg/d Intravenous Day -4 and -3

  • TreosulfanDrug

    10 g/m2/d Intravenous Day -4, -3, -2

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Event-free survival (EFS)Time frame: within 2 years after transplantation

Locations

33 sites in 6 countries. Site status is shown where the registry gives one.

  • Helsinki University Central Hospital, Dept. of Medicine

    Helsinki, Finland

  • Centre Hospitalier Lyon Sud

    Lyon, France

  • Hopital Saint-Louis

    Paris, France

  • Universitätsklinikum Koeln, Stammzelltransplantation

    Cologne, Germany

  • Universitätsklinikum Carl Gustav Carus Dresden, Med. Klinik I

    Dresden, Germany

  • Klinik für Knochenmarktransplantation

    Essen, Germany

  • Malteser Krankenhaus St. Franziskus-Hospital

    Flensburg, Germany

  • Universitätsklinikum Freiburg

    Freiburg im Breisgau, Germany

  • Universitätsmedizin Goettingen, Haematolgie und Onkologie

    Göttingen, Germany

  • Asklepios Kliniken Hamburg GmbH

    Hamburg, Germany

  • Universitätsklinikum Heidelberg

    Heidelberg, Germany

  • Friedrich-Schiller-Universität Jena

    Jena, Germany

  • Universitätsklinikum Leipzig, Haematologie, internistische Onkologie

    Leipzig, Germany

  • Johannes-Gutenberg-Universität Mainz, III. Medizinische Klinik

    Mainz, Germany

  • Klinikum Rechts der Isar der TU München, III. Med. Klinik

    München, Germany

  • Universitätsklinikum Münster

    Münster, Germany

  • Klinikum Nürnberg, 5. Medizinische Klinik

    Nuremberg, Germany

  • Klinikum Oldenburg gGmbH

    Oldenburg, Germany

  • Klinikum der Universität Regensburg

    Regensburg, Germany

  • Universität Rostock

    Rostock, Germany

  • Universität Tübingen

    Tübingen, Germany

  • Stiftung Deutsche Klinik für Diagnostik

    Wiesbaden, Germany

  • Klinikum der Universität Würzburg

    Würzburg, Germany

  • St. Istvan and St. Laszlo Hospital of Budapest

    Budapest, Hungary

  • Azienda Ospedaliera Papa Giovanni XXIII

    Bergamo, Italy

  • Hematology University of Brescia

    Brescia, Italy

  • Scientific Institute H. San Raffaele

    Milan, Italy

  • Ospedale Civile Pescara

    Pescara, Italy

  • Policlinico Umberto I Univ. La Sapienza

    Rome, Italy

  • Clinica Ematologica ed Unita di Terapie Cellulari 'Carlo Melzi'

    Udine, Italy

  • Policlinico GB Rossi (Borgo Roma), Div. di Ematologia

    Verona, Italy

  • Medical University of Gdansk

    Gdansk, Poland

  • Silesian Medical University

    Katowice, Poland

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.